Billionaire Ken Fisher’s Cheap Stock Picks for Q3 Include Microsoft Corporation (MSFT)

Page 1 of 2

Several weeks after the end of each quarter, hedge funds and other notable investors including billionaire Ken Fisher’s mutual fund Fisher Asset Management file 13Fs with the SEC to disclose many of their long equity positions as of the end of the quarter. We compile these filings and use them to help us develop investment strategies; for example, we have found that the most popular small cap stocks among hedge funds generate an average excess return of 18 percentage points per year (learn more about our small cap strategy). Our own portfolio based on these techniques outperformed the market by 33 percentage points in the last 11 months.

Fisher has already filed its 13F for the end of June, and so we have been going through the filing looking for potential value plays among the firm’s top picks. Read on for our quick take on its five largest positions as of the end of June in stocks with both trailing and forward P/E multiples of 13 or lower, or see a history of the fund’s stock picks.

Ken Fisher - FISHER ASSET MANAGEMENTOne of Fisher’s largest positions this year has been large pharmaceutical company Pfizer Inc. (NYSE:PFE), and it owned almost 31 million shares at the end of the second quarter of 2013. Pfizer Inc. (NYSE:PFE) has been selling or spinning out a number of its assets, including its former animal health unit Zoetis Inc (NYSE:ZTS), which in theory will enable management to focus more on the core business. Forecasts from Wall Street analysts imply a forward earnings multiple of 13. D.E. Shaw, a hedge fund managed by billionaire David Shaw, had 6.8 million shares of Pfizer Inc. (NYSE:PFE) in its portfolio as of the end of March (research more stocks D.E. Shaw owned).

The investment team reported a position of a bit more than 18 million shares in Wells Fargo & Co (NYSE:WFC), which recently became Warren Buffett’s Berkshire Hathaway’s largest publicly traded holding by market value (find Buffett’ favorite stocks). The bank is valued at 1.6 times the book value of its equity, while peers generally trade at book or below, but Wells Fargo & Co (NYSE:WFC) has been able to generate significant earnings from these assets. As a result its trailing P/E is only 12- a premium to some of its peers, but still fairly low in absolute terms. With earnings rising it could be worth considering as a value stock.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!